From Clinical Demand to Funded Persistence

Why is obesity becoming an access market rather than an efficacy market?

Obesity medicines have transformed the treatment conversation. Demand is high, clinical innovation is accelerating and a growing group of companies are competing to define the next generation of care^[1]. But the next phase of the market may be decided by a more practical question: how many clinically eligible patients can actually start treatment, remain on it and generate outcomes that justify continued funding?

For Novo Nordisk, Eli Lilly and emerging obesity-focused companies, commercial success increasingly depends on more than weight loss, supply or prescription volume. It depends on whether a patient can navigate a funded treatment journey.

A patient can be medically eligible for treatment yet never become a sustained user^[2]. Coverage may be excluded; authorization may be delayed; out-of-pocket costs may prove prohibitive; or treatment may be discontinued before meaningful long-term outcomes are realized. The implication is straightforward: obesity is becoming an access-and-persistence market^[2].

What is the funded-patient funnel in obesity?

The addressable market is often discussed in terms of prevalence. Prevalence describes the clinical opportunity; it does not describe the commercially accessible market. Six stages sit between eligibility and realized outcomes. Select a stage to see where it breaks.

This funnel changes how obesity competition should be understood. Two medicines with broadly similar clinical outcomes can have very different commercial trajectories if one has stronger reimbursement, fewer access barriers, lower patient cost or better persistence support.

Why does the access ceiling now matter as much as the efficacy ceiling?

Wegovy and Zepbound have established that large-scale demand for obesity treatment exists. However, demand does not automatically become a funded, persistent patient population. The practical constraints are now increasingly commercial and operational: benefit design, eligibility rules, prior authorization, product preference, patient affordability, supply continuity and service support^[3].

1. 01

   Coverage decides who enters the market

   An employer or health plan can cover, exclude or tightly limit obesity treatment, and BMI, comorbidity and prior-treatment criteria define who can enter the funded market.

2. 02

   Administration decides who starts and stays

   Authorization and renewal friction can delay initiation or interrupt ongoing therapy, while formularies and negotiated rebates may determine which brand reaches a covered patient.

3. 03

   Cost and channel decide who continues

   High patient cost can prevent initiation or trigger early discontinuation, and retail, specialty, telehealth and direct-to-patient models affect practical access.

The result is a new form of competition. The winning medicine may not simply be the one associated with the greatest weight loss in a trial. It may be the one that best fits the payer, provider, channel and patient model required to keep treatment funded and sustained.

How is Eli Lilly building access architecture around Zepbound?

Eli Lilly's Zepbound has become a central competitor in the obesity market, but Lilly's strategy extends beyond the product itself. The company has built direct and employer-facing access initiatives, including LillyDirect and Employer Connect, alongside efforts to support benefit design and self-pay pathways^[4].

The strategic significance is broader than any one program. It suggests that manufacturers may increasingly compete on their ability to help employers, plans and patients manage affordability, fulfillment and continuity, not only on the clinical profile of the medicine.

For Lilly, the opportunity is to convert high consumer and physician interest in Zepbound into sustained use across employer-sponsored, commercial, public and self-pay channels. Its emerging oral and next-generation obesity pipeline could widen that choice architecture further, particularly if route of administration, dosing or tolerability create new patient segments.

How is Novo Nordisk defending Wegovy in a more segmented market?

Novo Nordisk's Wegovy established a major obesity franchise and helped create the modern anti-obesity market. The company now faces a more contested environment in which access, price, product format and lifecycle management are increasingly important alongside clinical evidence^[6].

The rollout of oral Wegovy illustrates the relevance of product segmentation. An oral option may not simply compete on convenience; it may create different patient, provider and channel opportunities from injectable treatment^[6]. At the same time, Novo Nordisk must navigate payer preference, self-pay demand, price pressure and the challenge of sustaining access across diverse populations.

The implication is that obesity may evolve into several commercially viable segments: employer-covered patients, self-pay users, high-risk reimbursed cohorts, patients seeking oral treatment, patients prioritising convenience or tolerability, and people with obesity-related cardiometabolic comorbidities. The message is not that one route or mechanism will win every patient. It is that product portfolios may increasingly compete as choice architectures, designed around the different access conditions and treatment preferences that define the real obesity market.

Why is persistence a commercial problem, not just a clinical one?

Obesity treatment has a distinct persistence challenge. Initiation is only the first commercial milestone. Patients and providers must manage dose escalation, gastrointestinal tolerability, changing coverage, refill continuity, treatment expectations and the reality that treatment may be long term^[11].

This turns persistence into a clinical, commercial and payer issue. A plan that funds treatment but sees rapid discontinuation may question value^[11]. A company that can improve continuation through appropriate patient support, refill coordination and evidence generation may create an advantage that does not appear in a head-to-head efficacy chart.

The account map reflects that. Primary-care practices identify eligible patients, manage comorbidities, initiate therapy and support follow-up at scale, while endocrinologists and obesity specialists influence treatment strategy for complex, high-risk and treatment-experienced patients. Employers and benefit consultants shape benefit inclusion, program design, eligibility and continuation rules; health plans and PBMs determine formulary position, utilization management, rebate structures and patient cost sharing.

Pharmacies and specialty channels manage dispensing, refill continuity, patient education and fulfillment friction. Telehealth and digital-care providers can extend access and coaching but must integrate with safe prescribing and longitudinal care. National payers and HTA bodies define the reimbursed cohort, value threshold and treatment pathway in many European markets. The practical question is not only whether a therapy can be prescribed. It is whether the surrounding care and access system can reliably keep an appropriate patient on treatment long enough to realise meaningful benefit.

What are the leading obesity companies signaling?

In the US, companies must demonstrate why a plan should finance long-duration therapy at scale and how utilization can be managed responsibly. In Europe, companies must make a country-by-country case on comparative value, budget impact and implementation within the care pathway.

France's 2026 reimbursement move for Wegovy and Mounjaro in defined severe-obesity populations illustrates the principle of selective public access: reimbursement can emerge for tightly specified, high-risk cohorts rather than for the full clinically eligible population^[15].

The message is not that efficacy has become unimportant. It is that, as multiple clinically credible options emerge, access, affordability and persistence can become decisive sources of commercial preference.

What should an emerging obesity company do differently?

For an emerging obesity company, strong weight-loss data may be necessary but insufficient. It needs a credible route to the funded patient population it intends to serve. The strategic question is which patient segment is most likely to be funded, initiated and persistent on this therapy, and why.

A smaller company may not replicate the scale of an established franchise or a direct-to-patient platform. It can, however, make earlier and sharper choices about where its product can genuinely win, and build its evidence and access strategy around that market from the outset^[17].

What is still unresolved in the obesity market?

The future of obesity treatment may not hinge only on which medicine produces the greatest weight loss. The more consequential question is whether companies can convert clinical demand into funded, sustained treatment at a scale that payers, providers and patients can support^[17].

Those questions sit with the people shaping obesity care and its funding: primary-care physicians, endocrinologists and obesity specialists, employers and benefit consultants, health-plan and PBM decision-makers, specialty pharmacy leaders, national payers and HTA bodies, and former industry executives.

The next obesity winner may not be the product with the strongest headline result. It may be the company that best converts clinical demand into funded persistence, and demonstrates that the treatment is worth keeping funded.